TL;DR
Get wellness gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A guest essay published by The Quantum Insider on Oct. 30, 2026, argues that quantum computing in biotech remains at an experimental stage, despite early work on a model for triple-negative breast cancer. The author says wider impact will depend on advances in hardware, software, expertise, access and partnerships; the reported project has not yet reached proof of concept.
Quantum computing is still at an early stage in biotechnology, according to a guest essay published Oct. 30 by The Quantum Insider, which describes one early-stage company using quantum computing in a virtual model of triple-negative breast cancer. The model is intended to help predict drug-treatment options for individual patients, but it remains under development and has not yet reached proof of concept, the author says.
The essay was written by Kamran Tavangar, identified as LabCentral’s head of science strategy and partnerships. He says the company was among 30 early-stage, AI-focused companies in LabCentral’s AI BioHub program, developed in partnership with C10 Labs with support from the Commonwealth of Massachusetts. One company in the cohort was actively using a quantum computer, according to Tavangar.
The company’s virtual disease model focuses on triple-negative breast cancer (TNBC), which the essay says accounts for about 10% to 15% of breast cancers. TNBC lacks estrogen, progesterone and HER2 receptors, limiting the use of therapies that target those receptors. Tavangar describes the project’s early results as encouraging, while saying the team is refining the model with retrospective and prospective data and working toward a proof of concept.
Tavangar expects a hybrid CPU-GPU-QPU approach—combining conventional processors, graphics processing units and quantum processing units—to remain the practical approach for the foreseeable future. He says current classical computing advances and simulated quantum algorithms can match or outperform results from current quantum computers. The essay does not provide quantitative performance results for the cancer-model project.
What Biotech Needs From Quantum
The essay’s significance is less a claim of a new treatment than a snapshot of how early quantum adoption is in biotech. Only one of the 30 AI BioHub companies was using a quantum computer, by Tavangar’s account. The cancer model illustrates a possible application, but does not establish that quantum computing improves treatment selection or patient outcomes.
For readers following biotech investment and research, the distinction matters: a promising computational approach is not the same as a validated clinical tool. Any eventual use would depend on reliable data, working models and evidence that the technology adds value beyond existing methods. Tavangar’s account points to practical barriers as well as technical ones, including cost, difficult access to quantum hardware and a limited pool of people with expertise in both quantum computing and biology.
The author frames progress as a system-wide effort involving hardware, software, algorithms, regulation and public-private partnerships. That view places quantum computing alongside, rather than immediately ahead of, established computing methods and laboratory research. It also signals that adoption would take sustained development, not a single hardware milestone.
Products Worth Considering
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
Oura Ring 5 Smart Ring, Silver, Size 7
Therabody Theragun Relief Massage Gun, 3-Speed, Black
As an affiliate, we earn on qualifying purchases.
From AI Models to Quantum Tests
Tavangar compares quantum computing’s current position with Dick Fosbury’s high-jump technique. At the 1968 Mexico City Olympics, Fosbury cleared 2.24 meters and won gold using the backward-jumping method that became known as the Fosbury Flop. Tavangar says the technique relied on cushioned landing pads and years of practice; it took further refinement before the method became standard. The analogy is used to argue that a disruptive approach needs enabling infrastructure and continued improvement.
The essay places quantum work within a broader biotech AI trend. It says AI systems draw on biological data gathered through decades of research and can support protein-structure prediction, disease modeling and searches across large biological spaces. Tavangar describes a feedback loop in which improved models require more laboratory data, leading to further experimentation. He presents quantum computing as a possible addition to that process, not a replacement for AI or laboratory work.
The essay also makes clear that current quantum machines are not yet the default option for the program’s companies. Classical processors and GPUs remain important, while quantum hardware, software and algorithms continue to develop. Tavangar’s account is a perspective from a program leader, not an independent evaluation of the cancer model or a clinical study.
““We believe that a hybrid CPU-GPU-QPU approach will remain the approach of choice for the foreseeable future.””
— Kamran Tavangar, LabCentral’s head of science strategy and partnerships
Evidence Still Needed for TNBC
The essay does not identify the company using quantum computing, disclose the model’s performance, or provide a comparison with conventional computing methods. It also does not specify what “encouraging” early results mean, how the model performs on retrospective data, or when a proof of concept might be completed. The project’s prospective data work and development are described as ongoing.
It remains unclear whether adding quantum hardware improves the model’s predictions, whether those predictions would change clinical decisions, or whether any benefit could be demonstrated in patient care. The article offers no clinical validation, regulatory status or timeline for testing the model with patients. Tavangar’s account is a guest essay, and its claims about the project are not independently assessed in the material provided.
Model Refinement and Validation
According to Tavangar, the company is continuing to refine its disease model using retrospective and prospective data and moving toward proof of concept. The essay gives no target date for that milestone. Further details about the model, its results and comparisons with classical methods would be needed to judge whether quantum computing contributes a measurable advantage.
More broadly, Tavangar argues that biotech use will depend on improvements in quantum processors and supporting software, alongside better access and more people able to work across biology and quantum computing. For now, the described project is an early development effort, not evidence of a clinically established treatment-selection tool.
Key Questions
What is the quantum-computing project described in the essay?
An unnamed early-stage company is incorporating quantum computing into a virtual disease model of triple-negative breast cancer. The model is intended to help predict drug options for individual patients, but it remains in development.
Has the model been shown to improve cancer treatment?
No such result is reported. The essay describes early results as encouraging and says the company is working toward proof of concept, but it provides no clinical outcomes or evidence that the model improves treatment decisions.
How common was quantum-computer use in the AI BioHub cohort?
Tavangar says one of the 30 companies in the cohort was actively using a quantum computer. The essay does not describe the other companies’ individual technologies or projects.
Why does the author expect a hybrid computing approach?
Tavangar says classical processors and GPUs continue to advance, and simulated quantum algorithms can match or outperform results from current quantum computers. He expects quantum processors to take on a larger role as the hardware develops.
Source: thequantuminsider.com
